Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 20-F (Annual Report)
Period Ended: December 31, 2008
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on the discovery and development of REOLYSIN®, an oncolytic reovirus therapeutic for cancers with an activated Ras pathway. The company has no commercial product revenue and relies on equity financing to fund research and development (R&D) and clinical trials.
Key Financial Metrics
| Metric (Cdn$) | 2008 | 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss (Canadian GAAP) | $(17,550,204) | $(15,950,426) |
| Net Loss (U.S. GAAP) | $(17,188,704) | $(15,588,926) |
| Loss Per Share (Basic & Diluted) | $(0.42) | $(0.39) |
| Total Assets | $13,987,195 | $26,297,567 |
| Cash and Cash Equivalents | $7,429,895 | $6,715,096 |
| Short-term Investments | $5,846,634 | $18,498,733 |
| Total Liquidity (Cash + ST Investments) | $13,276,529 | $25,213,829 |
| Working Capital | $9,008,408 | $22,732,987 |
| Long-term Debt | $0 | $0 |
| Accumulated Deficit | $(102,556,751) | $(85,006,547) |
Note: All figures are in Canadian Dollars unless otherwise noted. The company reported no operating revenue for the period.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately 10% to $17.55 million in 2008 compared to $15.95 million in 2007. This was driven by higher clinical trial expenses ($5.80M vs $3.90M) and increased public company-related expenses.
- Significant Decline in Liquidity: Total cash and short-term investments dropped from $25.2 million in 2007 to $13.3 million in 2008. This decrease reflects cash used in operating activities of $15.3 million, partially offset by financing proceeds of $3.4 million.
- Accounting Policy Change: The company early adopted CICA Handbook Section 3064 "Goodwill and Intangible Assets" on April 1, 2008. This required the expensing of previously capitalized third-party legal costs for patents, resulting in a restatement of prior periods and a reduction in reported intellectual property assets.
- Financing Activity: In December 2008, the company issued 2,650,000 units for net cash proceeds of $3.42 million to fund clinical trials and general corporate purposes.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2009 Cash Requirements: Management estimates cash requirements for the "base level" of R&D activity in 2009 to be approximately $11.0 million. Current cash resources are projected to fund this level of activity into the first quarter of 2010.
- Clinical Progress: The company ended 2008 with 12 clinical trials underway or approved to commence. Key milestones included positive interim results in co-therapy trials (paclitaxel/carboplatin and docetaxel) and meeting the primary statistical endpoint in a Phase II sarcoma trial.
- Path to Registration: The company plans to pursue a Phase III randomized clinical trial for head and neck cancer in 2009. This expansion would require additional funding beyond the base level.
- Subsequent Event: On March 2, 2009, the company entered into an agreement to acquire an inactive private company ("PrivateCo") expected to bring approximately $2.3 million in net cash to the balance sheet upon closing.
Risks and Contingencies
- Capital Constraints: The company has a history of losses and no operating revenue. Continued access to capital markets is critical; failure to secure additional financing could force a reduction in R&D expenditures.
- Regulatory and Clinical Risk: REOLYSIN® is still in the development stage. There is no assurance that clinical trials will demonstrate safety and efficacy sufficient for regulatory approval by the FDA or Health Canada.
- Manufacturing Dependence: The company relies on third-party contract manufacturers for REOLYSIN® production. Disruptions in these relationships could delay clinical trials.
- Intellectual Property: While the company holds over 200 patents, there is a risk that patents may be challenged, invalidated, or that the company may infringe on third-party rights.
Investor Verification Checklist
- Cash Runway: Verify if the $13.3 million cash balance is sufficient to sustain the planned 2009 clinical trial program without immediate dilution.
- PrivateCo Acquisition: Confirm the closing of the March 2009 acquisition of PrivateCo and the actual cash proceeds received.
- Clinical Trial Data: Review detailed results of the Phase II sarcoma trial and the status of the Phase III head and neck cancer protocol submission to the FDA.
- Financing Terms: Assess the terms of any new equity issuances, specifically the dilution impact of the 2,650,000 units issued in late 2008 and any subsequent offerings.
- Accounting Restatements: Understand the full impact of the Section 3064 adoption on the valuation of intellectual property assets and future expense recognition.